UK Medtech Gets A Role In Post-Brexit Trade Deal Negotiations
Pressure ramps to broker international agreements as end of EU withdrawal period nears
With the Brexit implementation period ending in four months, the UK government has launched a trade advisory group for international life sciences deal talks and given UK medtech a seat at the table.
You may also be interested in...
New MHRA guidance says the EU CE marking will continue to be used for devices and diagnostics in Great Britain until June 2023, and thereafter a standalone regulatory system will come into place.
Securing a favorable post-Brexit free trade agreement with the US is the principal aim of the UK’s Department for International Trade, and the UK medtech industry is pressing its case for closer business links with its largest non-EU trading partner.
The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.